ANORMED TO BEGIN TWO PHASE III TRIALS OF MOZOBIL
AnorMED has announced it has completed enrollment for one of two pivotal Phase III trials being conducted with MOZOBIL for stem cell transplants. The multiple myeloma trial reached its target enrollment of 300 patients. Recruitment continues for the second Phase III trial in non-Hodgkin's lymphoma, having enrolled 241 of the target of 300 patients. The two Phase III trials are evaluating MOZOBIL in a standard stem cell mobilization regimen.
The most recently enrolled patients will undergo their transplants over the next four to six weeks, with a subsequent 100-day follow-up period required. The results of the study will be unblinded once all patients enrolled have completed their 100 day follow-up.
MOZOBIL is a stem cell mobilizer used in stem cell transplants, a procedure used to restore the immune system of cancer patients whose previous treatments have destroyed their immune cells. MOZOBIL works by triggering the rapid movement of stem cells out of bone marrow and into circulating blood. Once in the circulating blood, the stem cells can be collected for use in a stem cell transplant.